{"DataElement":{"publicId":"4449953","version":"1","preferredName":"Person Clinical Study Agent Hypersensitivity Exclusion Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response related to a person's hypersensitivity or allergy to study agent that prevents a subject from being allowed to participate in a clinical study, as outlined in the study protocol.","longName":"SDY_AG_HYP_EX_CD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"3235130","version":"1","preferredName":"Person Clinical Study Agent Hypersensitivity Exclusion Criteria","preferredDefinition":"information related to a person's hypersensitivity or allergy to study agent that prevents a subject from being allowed to participate in a clinical study, as outlined in the study protocol.","longName":"2236731v1.0:3235128v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3235128","version":"1","preferredName":"Clinical Study Agent Hypersensitivity Exclusion Criteria","preferredDefinition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research. :An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):An exaggerated response by the immune system to a drug or other substance.:Exclusion; the act of restricting entrance or barring from participation.","longName":"C15206:C1708:C3114 :C25370","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Study","conceptCode":"C15206","definition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hypersensitivity","conceptCode":"Hypersensitivity","definition":"An exaggerated response by the immune system to a drug or other substance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Exclusion Criteria","conceptCode":"C25370","definition":"Medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A329325E-C898-54AD-E040-BB89AD437E96","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-13","modifiedBy":"ONEDATA","dateModified":"2011-05-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A329325E-C8A9-54AD-E040-BB89AD437E96","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-13","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"10000083","version":"1","longName":"Physical & Concomitant Requirements","context":"Theradex"},{"publicId":"3876424","version":"1","longName":"Prior Treatments","context":"Theradex"}]},{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"},{"name":"PS&CC","type":"USED_BY","context":"PS-CC"},{"name":"Theradex","type":"USED_BY","context":"Theradex"},{"name":"AG_HYP_EX_CD_IND","type":"OID, Theradex","context":"Theradex"},{"name":"AG_HYP_CD_IND","type":"OID, Theradex","context":"Theradex"}],"ReferenceDocuments":[{"name":"Theradex - 4","type":"Alternate Question Text","description":"Does patient have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib or excipients or to dimethyl sulfoxide (DMSO)?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Does patient have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib, or excipients or to dimethyl sulfoxide (DMSO), or to compounds of similar chemical or biologic composition to navitoclax?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or other agents used in this study?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine and eribulin?","url":null,"context":"Theradex"},{"name":"Does the patient have a known","type":"Preferred Question Text","description":"Does the patient have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to the study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to TRC102 or pemetrexed and cisplatin?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to BMN 673 or other agents used in this study?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nilovumab?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, ipilimumab or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN8237, including but not limited to established allergic reaction to benzodiazepines, 5-FU, leucovorin or oxaliplatin?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775 or belinostat?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Does patient have a known clinically significant allergic reactions attributed to compounds of similar chemical or biologic compassion to AT13387 or paclitaxel?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Does patient have a known sensitivity to or history of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat, nivolumab, or ipilimumab?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Does patient have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to AT13387?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Does patient have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib DMSO, its excipients or DMSO?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Does patient have a history of hypersensitivity attributed to compounds of similar chemical or biologic composition to MLN0128 or AZD9291?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar composition to dolastatin or auristatin (e.g. Auristatin PHE, Auristatin PE, and symplostatin)?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Onalespib or AT7519?","url":null,"context":"Theradex"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar composition to dolastatin or auristatin?","url":null,"context":"COG"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Does patient have a history of hypersensitivity to AZD9291 (or drugs with similar chemical structure or class to AZD9291) or any excipients of these agents?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or cisplatin?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI-570 or history of anaphylaxis to any biological component?","url":null,"context":"Theradex"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Does patient have a history of drug sensitivity or allergic reaction to alpha, beta-blockers or ACE-inhibitors?","url":null,"context":"COG"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Does patient have a history of drug sensitivity or allergic reaction to alpha or beta-blockers?","url":null,"context":"COG"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to similar chemical or biologic composition to VX-970, cisplatin, or gemcitabine?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib and/or Onalsepib?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI-570?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970 or cisplatin?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide and blinatumomab or other agents used in this study?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to AT13387 (Onalsepib)?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib and MM-398?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Does patient have history of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970 or gemcitabine?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to similar chemical or biologic composition to IPdR?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib (difficulty breathing, lip swelling, itching or rash)?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Does patient have a history of hypersensitivity attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) or osimertinib (AZD9291)?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to similar chemical or biologic composition to VX-970, carboplatin, gemcitabine or to these specific components?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 and atezolizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib, cediranib, carboplatin, cisplatin, or etoposide?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and AT13387?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab or atezolizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, ipilimumab, or blinatumomab?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD9291 (osimertinib) or bevacizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib or other agents used in this study?","url":null,"context":"Theradex"},{"name":"Theradex - 52","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions to SGI-110 or decitabine?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"Does patient have a known hypersensitivity to MK-3475 (pembrolizumab) or history of allergic reactions to compounds of similar chemical or biologic composition to anti-PD1 or PD-L1 antibodies or entinostat?","url":null,"context":"Theradex"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to tremelimumab and MEDI4736  or previous toxicity attributed to MEDI4736 or other PD-1 or PD-L1 directed therapy that led to drug discontinuation?","url":null,"context":"Theradex"},{"name":"Theradex - 46","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to or other agents used in this study?","url":null,"context":"Theradex"},{"name":"Theradex - 54","type":"Alternate Question Text","description":"Does patient have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib or excipients or to dimethyl sulfoxide (DMSA)?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244 or other agents used in this study?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in this study?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to tremelimumab and MEDI4736(durvalumab) or previous toxicity attributed to MEDI4736(durvalumab) or other PD-1 or PD-L1 directed therapy that led to drug discontinuation?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"Does patient have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to talimogene laherparepvec (T-VEC) or any of its components?","url":null,"context":"Theradex"},{"name":"Theradex - 58","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax or vistusertib?","url":null,"context":"Theradex"},{"name":"Theradex - 60","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and ramucirumab?","url":null,"context":"Theradex"},{"name":"Theradex - 59","type":"Alternate Question Text","description":"Does patient have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to talimogene laherparepvec or any of its components or nivolumab, or history of severe hypersensitivity reaction to any monoclonal antibody?","url":null,"context":"Theradex"},{"name":"Theradex - 62","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab) and Interferon-gamma?","url":null,"context":"Theradex"},{"name":"Theradex - 56","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to tremelimumab and MEDI4736 or previous toxicity attributed to MEDI4736 or other PD-1 or PD-L1 directed therapy that led to drug discontinuation?","url":null,"context":"Theradex"},{"name":"Theradex - 68","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in this study?","url":null,"context":"Theradex"},{"name":"Theradex - 69","type":"Alternate Question Text","description":"Does patient have an allergy or hypersensitivity to components of the cobimetinib formulations?","url":null,"context":"Theradex"},{"name":"Theradex - 65","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to CDX-1127 (varlilumab) and/or nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 64","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775 or cisplatin?","url":null,"context":"Theradex"},{"name":"Theradex - 70","type":"Alternate Question Text","description":"Does patient have a known hypersensitivity to any of the components of tazemetostat or a history of allergic reactions attributed to compounds of similar chemical or biologic composition to tazemetostat?","url":null,"context":"Theradex"},{"name":"Theradex - 63","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232 or decitabine?","url":null,"context":"Theradex"},{"name":"Theradex - 66","type":"Alternate Question Text","description":"Does patient have a history of known immediate or delayed hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to AT13387, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO)?","url":null,"context":"Theradex"},{"name":"Theradex - 67","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to the following: camptothecin derivatives (e.g. topotecan, irinotecan, exatecan), any ingredients contained within the liquid irinotecan solution (e.g. sorbitol), or any antiemetics or antidiarrheals appropriate for administration with study therapy (e.g. loperamide, dexamethasone?","url":null,"context":"Theradex"},{"name":"Theradex - 74","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib or nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 75","type":"Alternate Question Text","description":"Does patient have any known hypersensitivity or contraindication to the components of the study drug AZD1775?","url":null,"context":"Theradex"},{"name":"Theradex - 71","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD8186 or Docetaxel?","url":null,"context":"Theradex"},{"name":"Theradex - 73","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to or other agents used in this study or known intolerance to either of the study drugs (or any of the excipients)?","url":null,"context":"Theradex"},{"name":"Theradex - 76","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in this study or known intolerance to either of the study drugs (or any of the excipients)?","url":null,"context":"Theradex"},{"name":"Theradex - 77","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib, topotecan or carboplatin?","url":null,"context":"Theradex"},{"name":"Theradex - 78","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to atezolizumab or cobimetinib?","url":null,"context":"Theradex"},{"name":"Theradex - 79","type":"Alternate Question Text","description":"Does patient have a history of severe allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, anetumab ravtansine or paclitaxel?","url":null,"context":"Theradex"},{"name":"Theradex - 81","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (Pembrolizumab) or KW-0761 (Mogamulizumab)?","url":null,"context":"Theradex"},{"name":"Theradex - 85","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to copanlisib, PI3K inhibitors, or nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 86","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and atezolizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 83","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or radium-223?","url":null,"context":"Theradex"},{"name":"Theradex - 87","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition of olaparib?","url":null,"context":"Theradex"},{"name":"Theradex - 82","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Nivolumab (Parts A+B) and/or Ipilimumab (Part B)?","url":null,"context":"Theradex"},{"name":"Theradex - 88","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to copanlisib, PI3K inhibitors, or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 89","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970) or cisplatin?","url":null,"context":"Theradex"},{"name":"Theradex - 90","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 or carboplatin?","url":null,"context":"Theradex"},{"name":"Theradex - 80","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Olaparib or a known hypersensitivity to olaparib or any of the excipients of the product?","url":null,"context":"Theradex"},{"name":"Theradex - 84","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to similar chemical or biologic composition to M6620 (VX-970), carboplatin, gemcitabine or to these specific components?","url":null,"context":"Theradex"},{"name":"Theradex - 94","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to savolitinib or hypersensitivity to the active or inactive excipients?","url":null,"context":"Theradex"},{"name":"COG CRF TEXT 4","type":"Alternate Question Text","description":"Does patient have hypersensitivity to axitinib, nivolumab, or any of its excipients?","url":null,"context":"COG"},{"name":"Theradex - 91","type":"Alternate Question Text","description":"Does patient have history of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970) or gemcitabine?","url":null,"context":"Theradex"},{"name":"Theradex - 92","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to CB-839 HCl or TMZ.?","url":null,"context":"Theradex"},{"name":"Theradex - 96","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to birinapant?","url":null,"context":"Theradex"},{"name":"Theradex - 97","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to copanlisib and/or nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 98","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pinometostat or azacitidine?","url":null,"context":"Theradex"},{"name":"Theradex - 100","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN4924 (pevonedistat), azacitidine, or mannitol?","url":null,"context":"Theradex"},{"name":"Theradex - 99","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 or irinotecan?","url":null,"context":"Theradex"},{"name":"Theradex - 105","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to CB-839 HCl, AZD9291, other agents used in study, or hypersensitivity to any of the inactive excipients thereof?","url":null,"context":"Theradex"},{"name":"Theradex - 103","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to copanlisib, fulvestrant, or PI3K inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 101","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pinometostat or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 102","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN4924 (pevonedistat) or MLN9708 (ixazomib) (including boron or boron-containing products)?","url":null,"context":"Theradex"},{"name":"Theradex - 104","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN4924 (pevonedistat) or belinostat?","url":null,"context":"Theradex"},{"name":"Theradex - 112","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to CB-839 HCl?","url":null,"context":"Theradex"},{"name":"Theradex - 110","type":"Alternate Question Text","description":"Does patient have a known hypersensitivity to olaparib or AZD6738 or any of the excipients of the products or a history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or AZD6738?","url":null,"context":"Theradex"},{"name":"Theradex - 108","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib, copanlisib, P13K inhibitors or MEDI4736 (durvalumab) or any of the excipients of any study product?","url":null,"context":"Theradex"},{"name":"Theradex - 113","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 or topotecan used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 111","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or TMZ or any of the excipients of any study product?","url":null,"context":"Theradex"},{"name":"Theradex - 107","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN9708, venetoclax, or dexamethasone, including boron and boron-containing products?","url":null,"context":"Theradex"},{"name":"Theradex - 114","type":"Alternate Question Text","description":"Does patient have hypersensitivity to Olaparib or any of the excipients of the product?","url":null,"context":"Theradex"},{"name":"Theradex - 117","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to M3814 or avelumab?","url":null,"context":"Theradex"},{"name":"Theradex - 115","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN4924 (pevonedistat), carboplatin or paclitaxel?","url":null,"context":"Theradex"},{"name":"Theradex - 120","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to KRT-232 (AMG 232) or decitabine?","url":null,"context":"Theradex"},{"name":"Theradex - 122","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to M3814 or pegylated liposomal doxorubicin?","url":null,"context":"Theradex"},{"name":"Theradex - 118","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Radium-223 dichloride, M3814, or avelumab?","url":null,"context":"Theradex"},{"name":"Theradex - 119","type":"Alternate Question Text","description":"Does patient have history of allergic reactions attributed to compounds of similar chemical or biologic composition to Copanlisib, P13K inhibitors or HER2 inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 121","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in this study?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to similar chemical or biologic composition to M6620 (VX-970)?","url":null,"context":"Theradex"},{"name":"Theradex - 124","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775 or olaparib?","url":null,"context":"Theradex"},{"name":"Theradex - 123","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine, venetoclax, or nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 128","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to M3814?","url":null,"context":"Theradex"},{"name":"Theradex - 126","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to CB-839HCL (telaglenastat) and MLN0128 (sapanisertib) used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 127","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to DS-8201a (e.g., other topoisomerase I inhibitors) or the inactive ingredients in the drug product?","url":null,"context":"Theradex"},{"name":"Theradex - 61","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to KRT-232 (AMG 232) or carfilzomib, lenalidomide, or dexamethasone?","url":null,"context":"Theradex"},{"name":"Theradex - 129","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to KRT-232 (AMG 232) or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 95","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI4736 (durvalumab) and tremelimumab?","url":null,"context":"Theradex"},{"name":"Theradex - 130","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or Lutetium Lu 177 Dotatate?","url":null,"context":"Theradex"},{"name":"Theradex - 132","type":"Alternate Question Text","description":"Has patient previously experienced a grade 4 life-threatening reaction or other adverse reaction that in the opinion of the investigator would preclude retreatment with ipilimumab, nivolumab, and/or other PD-1/PD-L1 antibodies?","url":null,"context":"Theradex"},{"name":"Theradex - 133","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to peposertib M3814 or pegylated liposomal doxorubicin?","url":null,"context":"Theradex"},{"name":"Theradex - 131","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775?","url":null,"context":"Theradex"},{"name":"Theradex - 134","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine?","url":null,"context":"Theradex"},{"name":"Theradex - 135","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to BAY 1895344 or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 72","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to anetumab ravtansine or pembrolizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 138","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to BAY 1893544 or pembrolizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 57","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab (MK-3475) and/or rhIL-12 or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 137","type":"Alternate Question Text","description":"Does patient have a history of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to BAY 1895344, 5-FU, leucovorin, or irinotecan?","url":null,"context":"Theradex"},{"name":"Theradex - 140","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions to compounds of similar chemical or biologic composition to elimusertib (BAY 1895344) or gemcitabine?","url":null,"context":"Theradex"},{"name":"Theradex - 136","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab or XL184 (cabozantinib)?","url":null,"context":"Theradex"},{"name":"Theradex - 116","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to berzosertib?","url":null,"context":"Theradex"},{"name":"Theradex - 139","type":"Alternate Question Text","description":"Does patient have a history of life-threatening toxicity, including hypersensitivity, related to BRAF or MEK inhibitor therapy, or known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO)?","url":null,"context":"Theradex"},{"name":"Theradex - 141","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat or other agents used in the study?","url":null,"context":"Theradex"},{"name":"Theradex - 142","type":"Alternate Question Text","description":"Does patient have history of allergic reactions attributed to compounds of similar chemical or biologic composition to rogaratinib (BAY 1163877)?","url":null,"context":"Theradex"},{"name":"Theradex - 143","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to M3814 (peposertib)?","url":null,"context":"Theradex"},{"name":"Theradex - 109","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab (MK-3475) or tazemetostat?","url":null,"context":"Theradex"},{"name":"Theradex - 149","type":"Alternate Question Text","description":"Does patient have a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product?","url":null,"context":"Theradex"},{"name":"Theradex - 146","type":"Alternate Question Text","description":"Does the patient have history of allergic reactions attributed to compounds of similar chemical or biologic composition to DS-8201a, the inactive ingredients in the drug product, olaparib, or severe hypersensitivity to other monoclonal antibodies?","url":null,"context":"Theradex"},{"name":"Theradex - 150","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to duvelisib or nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 125","type":"Alternate Question Text","description":"Does patient have a history of hypersensitivity to pembrolizumab (MK-3475) or any of its excipients, or other agents used in this study?","url":null,"context":"Theradex"},{"name":"Theradex - 144","type":"Alternate Question Text","description":"Does patient have a history of anaphylactic reactions attributed to anti-GD2 antibodies or to compounds of similar chemical or biologic composition to GD2CART, cyclophosphamide, fludarabine, or other agents used in this study?","url":null,"context":"Theradex"},{"name":"Theradex - 148","type":"Alternate Question Text","description":"Does patient have known severe hypersensitivity to abemaciclib, temozolomide or any excipient of abemaciclib or temozolomide or history of allergic reactions attributed to compounds of similar chemical or biologic composition to abemaciclib and temozolomide?","url":null,"context":"Theradex"},{"name":"Theradex - 145","type":"Alternate Question Text","description":"If patient is enrolled to the atezolizumab + bevacizumab combination arm, is History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 151","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to pomalidomide and/or nivolumab or compounds of similar chemical or biologic composition to pomalidomide and/or nivolumab?","url":null,"context":"Theradex"},{"name":"Theradex - 147","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Sn-117m-DTPA?","url":null,"context":"Theradex"},{"name":"Theradex - 55","type":"Alternate Question Text","description":"Does patient have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to talimogene laherparepvec or any of its components, 5-FU and / or oxaliplatin?","url":null,"context":"Theradex"},{"name":"Theradex - 154","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to similar chemical or biologic composition to M6620 (VX-970, berzosertib)?","url":null,"context":"Theradex"},{"name":"Theradex - 156","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970, berzosertib) or cisplatin?","url":null,"context":"Theradex"},{"name":"Theradex - 152","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to venetoclax, MLN9708 (ixazomib citrate) (including boron or boron-containing products) or dexamethasone?","url":null,"context":"Theradex"},{"name":"Theradex - 155","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to similar chemical or biologic composition to M6620 (VX-970, berzosertib) or cisplatin?","url":null,"context":"Theradex"},{"name":"Theradex - 153","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, ipilimumab, and/or ZEN003694, including severe hypersensitivity reactions to any monoclonal antibody?","url":null,"context":"Theradex"},{"name":"Theradex - 162","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab and tazemetostat or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 157","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat (e.g. medications that have a benzamide structure (tiapride, remoxipride, clebropride) or ZEN003694?","url":null,"context":"Theradex"},{"name":"Theradex - 163","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib or icosapent ethyl or any of its components (tocopherol, gelatin, glycerin, maltitol, and sorbitol) or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 106","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to telaglenastat (CB-839) HCl or TMZ?","url":null,"context":"Theradex"},{"name":"Theradex - 161","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ipatasertib or other agents used in study?","url":null,"context":"Theradex"},{"name":"Theradex - 160","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ipatasertib or hypersensitivity (grade greater than or equal to 3) to pembrolizumab and/or any of the components of the solution for injection?","url":null,"context":"Theradex"},{"name":"Theradex - 158","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 (ZEN-3694) and binimetinib?","url":null,"context":"Theradex"},{"name":"Theradex - 93","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Telaglenastat (CB-839) HCl, carfilzomib, or dexamethasone?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970, berzosertib) or irinotecan?","url":null,"context":"Theradex"},{"name":"Theradex - 165","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ASTX727 or nivolumab, including severe hypersensitivity reaction to any monoclonal antibody?","url":null,"context":"Theradex"},{"name":"Theradex - 166","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 or abemaciclib?","url":null,"context":"Theradex"},{"name":"Theradex - 164","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to DS-8201a, the inactive ingredients in the drug product, or neratinib?","url":null,"context":"Theradex"},{"name":"Theradex - 167","type":"Alternate Question Text","description":"Does the patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 (ZEN-3694) or talazoparib?","url":null,"context":"Theradex"},{"name":"Theradex - 168","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Telaglenastat (CB-839) HCl, Osimertinib (AZD9291), other agents used in study, or hypersensitivity to any of the inactive excipients thereof?","url":null,"context":"Theradex"},{"name":"Theradex - 169","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or durvalumab?","url":null,"context":"Theradex"},{"name":"Theradex - 170","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to selinexor (KPT-330) or temozolomide?","url":null,"context":"Theradex"},{"name":"Theradex - 171","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Lutetium Lu 177 dotatate?","url":null,"context":"Theradex"},{"name":"Theradex - 172","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 (ZEN-3694), nab-paclitaxel, or pembrolizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 173","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to belinostat or tazemetostat, or to compounds of similar chemical or biologic composition to these agents?","url":null,"context":"Theradex"},{"name":"Theradex - 174","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to novobiocin?","url":null,"context":"Theradex"},{"name":"COG CRF Text 5","type":"Alternate Question Text","description":"Does the patient have previously identified allergy or hypersensitivity to components of the study treatment formulations?","url":null,"context":"COG"},{"name":"Theradex - 175","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib malate or Lutetium Lu 177 dotatate?","url":null,"context":"Theradex"},{"name":"Theradex - 176","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to M1774 or temozolomide, including dacarbazine?","url":null,"context":"Theradex"},{"name":"Theradex - 177","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or Lutetium Lu 177 Dotatate?","url":null,"context":"Theradex"},{"name":"Theradex - 178","type":"Alternate Question Text","description":"Does patient have history of allergic reactions attributed to compounds of similar chemical or biologic composition to darolutamide or leuprolide acetate?","url":null,"context":"Theradex"},{"name":"Theradex - 179","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to KRT-232 (AMG 232) or decitabine?","url":null,"context":"Theradex"},{"name":"Theradex - 180","type":"Alternate Question Text","description":"Does patient have life-threatening immune-related adverse events (IRAEs) related to prior anti-PD-(L)1 antibody?","url":null,"context":"Theradex"},{"name":"Theradex - 181","type":"Alternate Question Text","description":"Does patient have a history of IRAE of G4 severity (excluding thyroid or endocrine disorders now controlled) or IRAE of any severity that required permanent treatment discontinuation with prior ICI therapy due to toxicity?","url":null,"context":"Theradex"},{"name":"Theradex - 182","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to M1774 or avelumab?","url":null,"context":"Theradex"},{"name":"Theradex - 183","type":"Alternate Question Text","description":"Does patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to mosunetuzumab or other agents used in study?","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008C4FAD-BE21-835A-E050-BB89AD432DFD","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"SOKKERL","dateModified":"2023-09-06","changeDescription":"2020-7-27 Added AQT for protocol 10389. AK 9591_Theradex_08.13.14_ghd","administrativeNotes":"11/09/22 added AQT for study ticket CADSR0001669 cjl;","unresolvedIssues":null,"deletedIndicator":"No"}}